OS by Kaplan-Meier analyses of patients with CMML according to SRSF2 mutations. (A) OS of patients with SRSF2mut did not significantly differ from patients with SRSF2wt. (B) OS of patients positive for SRSF2 Pro95His compared with patients with all other SRSF2 mutations and SRSF2wt (= all other) within the RUNX1-mutated subcohort showed a favorable trend. OS is indicated in months and was compared with the 2-sided log-rank test. P values are denoted in each graph, respectively.